

# BERRY, KARLA

DOB: 04/10/1962  
Sex: F  
Phone: (817) 845-4858  
Patient ID: 197565573

Age: 58  
Fasting: N

Specimen: DL895440X  
Requisition: 0002012  
Report Status: FINAL / SEE REPORT

Collected: 06/24/2020 14:13  
Received: 06/26/2020 06:30  
Reported: 07/01/2020 01:23

Client #: 10175330  
LUKNER, RALF B  
LUKNER MEDICAL CLINIC  
2545 PERRYTON PKWY STE 31 32  
PAMPA, TX 79065-2820  
Phone: (806) 329-3050  
Fax: (806) 419-1042

FASTING: NO


## LIPID PANEL, STANDARD

FINAL

Lab: IG


### CHOLESTEROL, TOTAL (2093-3)

Reference Range: <200 mg/dL



### HDL CHOLESTEROL (2085-9)

Reference Range: > OR = 50 mg/dL



Reference range varies across results

### TRIGLYCERIDES (2571-8)

Reference Range: <150 mg/dL



### LDL-CHOLESTEROL (13457-7)

mg/dL (calc)

Reference range: <100



Desirable range <100 mg/dL for primary prevention;  
<70 mg/dL for patients with CHD or diabetic patients  
with > or = 2 CHD risk factors.


LDL-C is now calculated using the Martin-Hopkins  
calculation, which is a validated novel method providing  
better accuracy than the Friedewald equation in the  
estimation of LDL-C.

Martin SS et al. JAMA. 2013;310(19): 2061-2068  
(<http://education.QuestDiagnostics.com/faq/FAQ164>)


*[Signature]*  
7/20/20

**CHOL/HDL C RATIO (9830-1)**

Reference Range: &lt;5.0 (calc)

**NON HDL CHOLESTEROL (43396-1)**

Reference Range: &lt;130 mg/dL (calc)



For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.


**▲ CBC (INCLUDES DIFF/PLT)**

FINAL


Lab: IG

**WHITE BLOOD CELL COUNT (6690-2)**


Reference Range: 3.8-10.8 Thousand/uL

**RED BLOOD CELL COUNT (789-8)**

Reference Range: 3.80-5.10 Million/uL

**HEMOGLOBIN (718-7)**


Reference Range: 11.7-15.5 g/dL



**HEMATOCRIT (4544-3)**


Reference Range: 35.0-45.0 %

FINAL

**MCV (787-2)**


Reference Range: 80.0-100.0 fL

FINAL

**▲ MCH (785-6)**


Reference Range: 27.0-33.0 pg

FINAL

**▲ MCHC (786-4)**


Reference Range: 32.0-36.0 g/dL

FINAL

**▲ RDW (788-0)**


Reference Range: 11.0-15.0 %

FINAL



**PLATELET COUNT (777-3)**


Reference Range: 140-400 Thousand/uL



FINAL

**MPV (776-5)**


Reference Range: 7.5-12.5 fL



FINAL

**▲ ABSOLUTE NEUTROPHILS (751-8)**

Reference Range: 1500-7800 cells/uL




FINAL

*likely  
2/2  
predominance*

**ABSOLUTE LYMPHOCYTES (731-0)**


Reference Range: 850-3900 cells/uL



FINAL

**ABSOLUTE MONOCYTES (742-7)**

Reference Range: 200-950 cells/uL



FINAL


*[Signature]*



**ABSOLUTE EOSINOPHILS (711-2)**


Reference Range: 15-500 cells/uL

FINAL

**ABSOLUTE BASOPHILS (704-7)**


Reference Range: 0-200 cells/uL

FINAL

**NEUTROPHILS (770-8)**

%

FINAL




Reference range varies across results

**LYMPHOCYTES (736-9)**

%

FINAL




Reference range varies across results

**MONOCYTES (5905-5)**

%

FINAL




Reference range varies across results

**EOSINOPHILS (713-8)**

%

FINAL



Reference range varies across results


**BASOPHILS (706-2)**

%

0.5

FINAL

From 09/02/2019 To 06/25/2020



Reference range varies across results

**▲ LYME DISEASE ANTIBODY (IGG), IMMUNOBLOT**

FINAL

Lab: IG

**LYME DISEASE AB(IGG),BLOT (6320-6)**

Reference Range: NEGATIVE

NEGATIVE

FINAL

No Historical Data

**▲ 18 KD (IGG) BAND (9588-5)**

REACTIVE

FINAL

No Historical Data

**▲ 23 KD (IGG) BAND (9589-3)**

REACTIVE

FINAL

No Historical Data

**▲ 28 KD (IGG) BAND (9590-1)**

REACTIVE

FINAL

No Historical Data

**30 KD (IGG) BAND (9591-9)**

NON-REACTIVE

FINAL

No Historical Data

**39 KD (IGG) BAND (9592-7)**

NON-REACTIVE

FINAL

No Historical Data

**41 KD (IGG) BAND (9593-5)**

NON-REACTIVE

FINAL

No Historical Data

**45 KD (IGG) BAND (9594-3)**

NON-REACTIVE

FINAL

No Historical Data

**58 KD (IGG) BAND (9595-0)**

NON-REACTIVE

FINAL

No Historical Data

**66 KD (IGG) BAND (9596-8)**

NON-REACTIVE

FINAL

No Historical Data

**▲ 93 KD (IGG) BAND (9597-6)**

REACTIVE

FINAL

No Historical Data

As per CDC criteria, a Lyme disease IgG immunoblot must show reactivity to at least 5 of 10 specific borrelial proteins to be considered positive. Although considered negative, reactivity to fewer borrelial proteins may indicate recent *B. burgdorferi* infection and warrant testing of a later sample. In rare instances, reactivity may represent antibodies induced by exposure to other spirochetes.

**COMMENT**

No Historical Data

FINAL

Lyme immunoblot testing should only be performed on samples from patients who have had a Positive or Equivocal result in a screening assay.

only 4 reactive.  
Need 5 for  
positive  
Lyme disease  
diagnosis


## ▲ VITAMIN D,25-OH,TOTAL,IA

FINAL

Lab: IG

### ▲ VITAMIN D,25-OH,TOTAL,IA (1989-3)

Reference Range: 30-100 ng/mL



Vitamin D Status 25-OH Vitamin D:

Deficiency: <20 ng/mL  
Insufficiency: 20 - 29 ng/mL  
Optimal: > or = 30 ng/mL

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssured(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

#### COMMENT

No Historical Data

FINAL

See Note 1

Note 1

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ199> (This link is being provided for informational/educational purposes only.)

## ▲ HEMOGLOBIN A1c W/eAG WITH REFLEX TO GLYCOMARK®


FINAL

Prediabetic

Lab: IG

### ▲ HEMOGLOBIN A1c (4548-4)

Reference Range: <5.7 % of total Hgb



For someone without known diabetes, a hemoglobin A1c value between 5.7% and 6.4% is consistent with prediabetes and should be confirmed with a follow-up test.

For someone with known diabetes, a value <7% indicates that their diabetes is well controlled. A1c targets should be individualized based on duration of diabetes, age, comorbid conditions, and other considerations.

This assay result is consistent with an increased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes for children.

eAG (mg/dL) (27353-2)

(calc)

123

No Historical Data

FINAL

BERRY,KARLA (DL895440X)

7 / 15

7/20/20

eAG (mmol/L) (53553-4)  
(calc)

6.8  
No Historical Data

FINAL

## ALBUMIN, RANDOM URINE W/CREATININE


FINAL

Lab: IG

CREATININE, RANDOM URINE (2161-8)  
mg/dL See Note 1

Test Not Performed


From 09/03/2019 To 09/04/2019



ALBUMIN, URINE (14957-5)  
mg/dL See Note 1

Test Not Performed

From 09/03/2019 To 09/04/2019



## RHEUMATOID ARTHRITIS DIAGNOSTIC IDENTRA<sup>®</sup> PANEL 2


FINAL

Lab: EZ

RHEUMATOID FACTOR (11572-5)  
Reference Range: <14 IU/mL

<14


FINAL



CYCLIC CITRULLINATED PEPTIDE (CCP) AB  
(IGG) (33935-8)  
Units

<16

FINAL



Reference Range:  
NEGATIVE:  
<20  
WEAK POSITIVE:  
20-39  
MODERATE POSITIVE:  
40-59  
STRONG POSITIVE  
>59




**14.3.3 ETA PROTEIN (75880-5)**

&lt;0.2

FINAL

Reference Range: &lt;0.2 ng/mL



The 14-3-3eta protein is a marker of synovial inflammation that is released into synovial fluid and peripheral blood in rheumatoid arthritis (RA) and erosive psoriatic arthritis. One in five RF and CCP seronegative early stage RA patients is found to be positive for 14-3-3eta protein. Patients with active joint RA disease have higher values of 14-3-3eta protein than those with inactive RA or psoriasis without arthritis. 14-3-3eta protein has a 93% specificity in patients with RA. Values  $\geq 0.2$  ng/mL are elevated and indicative of RA disease or erosive psoriatic arthritis. Values  $>0.50$  ng/mL are associated with more aggressive RA disease and poorer outcomes. Unlike RF and CCP, 14-3-3eta protein is a therapeutically modifiable marker to monitor response to therapy. A decrease in 14-3-3eta protein in response to DMARDs (disease-modifying antirheumatic drugs) and anti-TNF (tumor necrosis factor) drugs indicates better clinical outcomes; an increase is associated with worse outcomes despite apparent clinical remission.

For further information please visit:  
<http://www.questdiagnostics.com/testcenter/testguide.action?dc=TS-RmArthPnl>

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

**COMPREHENSIVE METABOLIC PANEL**


FINAL

Lab: IG

**GLUCOSE (2345-7)**

Reference Range: 65-139 mg/dL

FINAL




Non-fasting reference interval

**UREA NITROGEN (BUN) (3094-0)**


Reference Range: 7-25 mg/dL

FINAL



**CREATININE (2160-0)**

Reference Range: 0.50-1.05 mg/dL




FINAL

For patients >49 years of age, the reference limit for Creatinine is approximately 13% higher for people identified as African-American.

**eGFR NON-AFR. AMERICAN (77147-7)**


Reference Range: &gt; OR = 60 mL/min/1.73m2



FINAL

**eGFR AFRICAN AMERICAN (48643-1)**

Reference Range: &gt; OR = 60 mL/min/1.73m2




FINAL

**BUN/CREATININE RATIO (3097-3)**

Reference Range: 6-22 (calc)


NOT APPLICABLE



FINAL

**SODIUM (2951-2)**


Reference Range: 135-146 mmol/L




FINAL

**POTASSIUM (2823-3)**


Reference Range: 3.5-5.3 mmol/L

**CHLORIDE (2075-0)**


Reference Range: 98-110 mmol/L

**CARBON DIOXIDE (2028-9)**


Reference Range: 20-32 mmol/L

**CALCIUM (17861-6)**

Reference Range: 8.6-10.4 mg/dL


**PROTEIN, TOTAL (2885-2)**

Reference Range: 6.1-8.1 g/dL



**ALBUMIN (1751-7)**


Reference Range: 3.6-5.1 g/dL



FINAL

**GLOBULIN (10834-0)**


Reference Range: 1.9-3.7 g/dL (calc)



FINAL

**ALBUMIN/GLOBULIN RATIO (1759-0)**


Reference Range: 1.0-2.5 (calc)



FINAL

**BILIRUBIN, TOTAL (1975-2)**


Reference Range: 0.2-1.2 mg/dL



FINAL

**ALKALINE PHOSPHATASE (6768-6)**

Reference Range: 37-153 U/L




FINAL

Reference range varies across results



**AST (1920-8)**


Reference Range: 10-35 U/L



FINAL

**ALT (1742-6)**

Reference Range: 6-29 U/L



FINAL

**URINALYSIS, COMPLETE**

FINAL

Lab: IG

**COLOR (5778-6)**

See Note 1

**Test Not Performed**

Reference range varies across results


**DIRECT LDL**

FINAL

Lab: IG

**DIRECT LDL (18262-6)**

Reference Range: &lt;100 mg/dL



FINAL

Good!

Desirable range <100 mg/dL for primary prevention;  
<70 mg/dL for patients with CHD or diabetic patients  
with > or = 2 CHD risk factors.

**URIC ACID**

FINAL

Lab: IG

**URIC ACID (3084-1)**

Reference Range: 2.5-7.0 mg/dL



FINAL

No gout

Therapeutic target for gout patients: &lt;6.0 mg/dL

**SED RATE BY MODIFIED WESTERGREN**

FINAL

Lab: IG


BERRY, KARLA (DL895440X)

13 / 15

7/20/20

### SED RATE BY MODIFIED WESTERGREN (4537-7)

Reference Range: < OR = 30 mm/h



FINAL


### C-REACTIVE PROTEIN

FINAL

Lab: IG

#### C-REACTIVE PROTEIN (1988-5)

Reference Range: <8.0 mg/L



FINAL

### ANA MULTIPLEX W/REFLEX 11 AB CASCADE

FINAL

Lab: IG

#### ANACHOICE® SCREEN (8061-4)

Reference Range: NEGATIVE

NEGATIVE

No Historical Data

FINAL

A negative ANA Multiplex, with Reflex to 11 Antibody Cascade indicates the absence of detectable antibodies to component analytes consisting of double stranded DNA (dsDNA), chromatin, ribonucleoprotein (RNP), Smith/RNP (Sm/RNP), Smith (Sm), SS-A, SS-B, Jo-1, centromere B, Scl-70 and ribosomal P.

A negative result should be interpreted in the context of the clinical and laboratory findings and does not rule out autoimmune disease characterized by other autoantibody specificities such as rheumatoid arthritis, autoimmune hepatitis, primary biliary cirrhosis, autoimmune thyroiditis, Addison's disease, pernicious anemia, autoimmune neuropathies, vasculitis, celiac disease, and bullous disease.

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ177> (This link is being provided for informational/educational purposes only.)


### T4, FREE

FINAL

Lab: IG

#### T4, FREE (3024-7)


Reference Range: 0.8-1.8 ng/dL



FINAL

TSH (3016-3)

Reference Range: 0.40-4.50 mIU/L



Note 1 TEST NOT PERFORMED

No urine received.

**Performing Sites**

EZ Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042 Laboratory Director: Irina Maramica MD,PhD,MBA

IG Quest Diagnostics-Dallas Lab, 4770 Regent Blvd, Irving, TX 75063-2445 Laboratory Director: Dr. Robert L Breckenridge

**Key**

Priority Out of Range Out of Range PENDING Pending Result PRELIMINARY Preliminary Result FINAL Final Result REISSUED Reissued Result

Note: Data displayed only for results that meet strict identification matching. Historical result view may vary based on corrected or updated patient demographics. The reference range displayed may vary due to potential changes in laboratory testing methods. Please refer to the published reference range on each lab report.

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - "®" and "™" - are the property of their respective owners. Privacy policy can be found at: <http://questdiagnostics.com/home/privacy-policy/online-privacy.html>. © 2020 Quest Diagnostics Incorporated. All rights reserved.

  
7/20/20